The US$11B global vape market is ablaze with innovation
This is an older exclusive article for FinFeed subscribers which is now opened up. If you'd like to see new exclusive articles every week, please subscribe to our newsletter.
As the legal weed market matures, it’s quickly driving advances in cannabis technologies, especially in terms of developing easier, safer and smarter ways to ingest.
One of the fastest growing segments in the cannabis industry is the seemingly humble vaporiser, which in turn is helping to create new markets for legalised weed.
According to a report by BIS Research, the global recreational and medicinal vapor market was estimated at US$11.43 billion in 2016 and is expected to grow over US$86.43 billion by 2025.
“Vaping” commonly refers to a method of cannabis consumption where the user inhales “vapor” or aerosol. To create this vapor, the active compounds in cannabis are heated at low temperatures. Unlike what happens when pot is smoked, no combustion or burning takes place at these lower temperatures.
This quick-acting and relatively discreet way to medicate (or to just have a good time, if that’s your jam) is generally considered safer and healthier than smoking.
Today’s vape market includes e-cigarettes, vape pens and advanced personal vaporisers (otherwise known as “mods”). Vape cartridges are filled with cannabis oil extracted from the plant.
A report by BDS Analytics and Arcview Market Research projects that nearly 60% of extract (or concentrate) spending in 2018 will be for prefilled vaporisers.
Spending on vape is expected to equal or perhaps surpass spending on flower by 2022.
This kind of intense growth, in turn, means that a lot of money is being funnelled into ways to improve the vape delivery system.
One company that’s targeting this growing market is medical diagnostic and monitoring technology developer, Lifespot Health (ASX:LSH).
Approaching the vaping space from a medical perspective (at least, for now), Lifespot has developed a vaporiser embedded with certified software infrastructure.
The company has a first-to-market advantage with the integrated Seng-Vital Cannamed® Bluetooth cannabis vaporising system, which provides a straight-forward, secure and self-controlled method to deliver medicines.
Lifespot subsidiary, Seng Vital, developed the vaporiser, which is activated by a patient’s fingerprint. It can then be used to inhale cannabis from oils or herbs.
The monitoring and collection software, in turn, gathers and collates data and readings from the vaporiser, which patients and their authorised physicians can then review and evaluate.
Something else that makes the vaporiser unique is its embedment in the medically certified software infrastructure of BodyTel GmbH — another Lifespot subsidiary.
This infrastructure allows both patients and authorised physicians to retrieve and evaluate the readings and data collected by the vaporiser.
This integrated system isn’t restricted to vaping – it can also input data from edibles and drinks, which opens the company up to a number of significant global pot opportunities.
The method of inhalation used with the smart vaporiser, in turn, provides a number of clinical advantages. This system is especially well-suited to patient populations who are unable to swallow tablets, or for medications that are extensively metabolised prior to entry into the bloodstream.
“Studies tell us that oral forms of cannabis-based therapeutics have been shown to have low bioavailability following oral administration, so the dose required may be considerably higher than required for inhalation,” said Lifespot chairman, Rob Hannington. “Accordingly, the potential use of a lower dose as an inhaled format may in turn have a safety benefit.”
“Our integrated hardware and quality management platform provides a safe, measurable and controllable method for vaporising cannabis oil.”
Lifespot has demonstrated the benefits of this vaping system to a number of major pot players across Canada, USA, Israel, Australia and New Zealand — markets that are considerably advanced in approvals for both medical and recreational weed. Lifespot is also well-positioned for the next wave of approvals pending in European countries.
“We understand from our meetings that we are first to market a delivery device with these unique feature, and the major cannabis players see great value in our unique assets that are real enablers for them to register and commercialise their cannabis vaporising products,” Hannington said.
When the experts at Next Investors have a stock pick, it may pay to listen.
The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%.
They have just revealed their hand-picked, FY2021 stock portfolio of high conviction long-term investments.
Click the link below to see what they are currently investing in.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.